Bizarre Patents
A self defense weapon formed as a memo pad and which is easily held by a person's fingers, therefore making it possible to provide protection from a mugger and also to quickly and easily write a record or a message without failure of missing or forgetting significant information under a stressful situation.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6022954 | Process for the preparation of purified albumin solutions The invention relates to a process for preparing purified albumin from a human or animal physiological solution, such as a plasma or a plasma fraction. The process includes a process of delipidation using an anionic detergent and two chromatographic separ... | 02/08/2000 |
| 5965530 | Therapeutic uses of keratinocyte growth factor Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KG... | 10/12/1999 |
| 5849700 | Pharmaceutical formulation A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product a... | 12/15/1998 |
| 5849704 | Pharmaceutical formulation A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product a... | 12/15/1998 |
| 5844098 | Reconstituted platelet membrane vesicles A reconstituted platelet membrane vesicle preparation is provided. The preparation, directed at promoting hemostasis, may be prepared from proteins and lipids derived from either synthetic sources or from mammalian platelet membranes. The product may be u... | 12/01/1998 |
| 5843899 | Use of insulin-like growth factors I and II for inhibition of inflammatory response The present invention relates to methods for using IGF as inhibitors of inflammatory response, ischemic injury, and organ rejection.... | 12/01/1998 |
| 5837675 | Synergistic effect of insulin-like growth factor-I and erythropoietin Erythropoietin (EPO) and insulin-like growth factor (IGF); pharmaceutical compositions thereof and therapeutic and prophylactic methods to increase the hematocrit are disclosed herein. Increase in hematocrit and reticulocyte count is observed by IGF-I tre... | 11/17/1998 |
| 5830857 | Method of treating epilepsy A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.... | 11/03/1998 |
| 5824643 | Therapeutic uses of keratinocyte growth factor Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KG... | 10/20/1998 |
| 5824642 | Treatment of partial growth hormone insensitivity syndrome Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering an effective dose of growth hormone, preferably growth hormone w... | 10/20/1998 |
| 5814605 | Therapeutic uses of keratinocyte growth factor Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KG... | 09/29/1998 |
| 5811396 | TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further ... | 09/22/1998 |
| 5811395 | Relaxin analogs and derivatives methods and uses thereof The present invention relates to a relaxin analogs and derivatives, and uses thereof. The present invention further relates to compositions comprising a relaxin analogs and derivatives, and relaxin wherein such composition exhibits an additive or synergis... | 09/22/1998 |
| 5804550 | Peptide antagonists at glutamate and NMDA receptors The invention relates to the use of a new type of peptide antagonists at glutamate receptors and a subtype of glutamate receptors (NMDA (N-methyl-D-aspartate)) for the manufacture of a medicament to influence the glutamate receptor and the NMDA-receptor c... | 09/08/1998 |
| 5798334 | Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto The invention relates to a pharmaceutical composition for normalizing the fibrogenic effect of an agonist which comprises an effective amount of an agonist to stimulate normal collagen synthesis together with an effective amount of an antagonist to reduce... | 08/25/1998 |
| 5783559 | Solution containing IGF-1 The invention relates to solutions containing IGF-1 or any functional analogue thereof in which pH is 5.5 to 6.5, preferably 5.7 to 6.2. The amount of phosphate as buffer substance should be in a concentration of less than 50 mmol/L Preferably the formula... | 07/21/1998 |
| 5783556 | Formulated insulin-containing composition Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and... | 07/21/1998 |
| 5783560 | Use of human growth hormone for preoperative administration The invention relates to the use of growth hormone (GH) or effective analogues thereof for the manufacture of a medicament intended for preoperative administration in order to reduce protein loss, especially for the manufacture of a medicament for the pre... | 07/21/1998 |
| 5780431 | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form The present invention relates to novel formulations of corticotropin releasing factor (CRF) having improved stability during storage over extended periods of time as liquids, which retain significant pharmaceutical activity during such storage and/or whic... | 07/14/1998 |
| 5763399 | Composition and method for revitalizing scar tissue A composition and method are provided that are effective in revitalizing scar tissue by introducing a bioactive substance having angiogenic activity into the scar tissue. The bioactive substance can be introduced by itself, or it can be introduced into th... | 06/09/1998 |
| 5763401 | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content A stable albumin-free Recombinant Factor VIII (rFVIII) formulation in lyophilized form having both crystalline and amorphous components and comprising, when reconstituted with water, about 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, ... | 06/09/1998 |
| 5760187 | Purification process of a human growth hormone A human growth hormone can be purified by allowing a solution containing the human growth hormone to contact with a blue pigment-bonded carrier in order to selectively adsorb the human growth hormone, then eluting the human growth hormone with an eluant o... | 06/02/1998 |
| 5756463 | Use of insulin and IGF-1 A method is disclosed for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.... | 05/26/1998 |
| 5753624 | Materials and methods for treatment of plaquing disease Methods and compositions are provided for alleviation of disease states involving plaque formation, such as are manifested in Alzheimer's Disease and other amyloid disorders, and arteriosclerotic disease. Methods for the treatment of herpes virus infectio... | 05/19/1998 |
| 5750501 | Method and composition for treatment of patients having decompensated liver disease A method and composition for treating a Hepatitis B patient having hepatic decompensation utilizes Hepatitis B virus-reducing amounts of T댑, administered to a patient having decompensated liver disease so as to render the patient seroneg... | 05/12/1998 |
| 5747459 | Method for insuring adequate intracellular glutathione in tissue A method is provided for increasing and/or maintaining the level of intracellular glutathione. Pursuant to the invention, compositions including denatured and at least partially hydrolyzed proteins are administered to a patient in an amount sufficient to ... | 05/05/1998 |
| 5747456 | Continuous low-dose administration of parathyroid hormone or its agonist A method of promoting bone formation in a human patient, which includes the step of administering continuously to the patient parathyroid hormone or its agonist for a period of at least one month at a dosage between 10 and 400 units/24 hrs. Also disclosed... | 05/05/1998 |
| 5741776 | Method of administration of IGF-I A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exp... | 04/21/1998 |
| 5741778 | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product Methods are provided for preventing or reducing N-methyl-D-aspartate (NMDA) receptor agonist-mediated neuronal cell death by administering a glial cell line-derived neurotrophic factor (GDNF) protein product.... | 04/21/1998 |
| 5741777 | Modulation of wound contraction by blocking protein tyrosine phosphatase The present invention relates generally to methods and compositions for inhibiting wound contraction and the scarring that frequently results from such contraction. More particularly, the invention relates to the use of a protein tyrosine phosphatase inhi... | 04/21/1998 |
| 5739286 | Bone augmentation material There is disclosed a process for the mineralization of collagen fibers whereby collagen fibers formed from collagen are contacted with a solution of calcium and phosphate ions under conditions to effect nucleation and in-vitro growth of mineral crystals w... | 04/14/1998 |
| 5739105 | Cyclosporin containing composition and process for the preparation thereof A composition comprising 1.0 to 40 wt. % of a cyclosporin A, 0.1 to 30 wt. % of an emulsifier and 5 to 80 wt. % of a porous dextrin, based on the total weight of the composition has a remarkably improved dissolution rate and superior bioavailability.... | 04/14/1998 |
| 5736515 | Use of growth hormone for increasement of concentration of GH, IGF-I and IGFBP-3 in cerebrospinal fluid A method for treatment of a patient for obtaining an increased concentration of a factor selected from the group consisting of growth hormone, insulin-like growth factor (IGF-I) and IGFBP-3 in cerebrospinal fluid by administration of growth hormone or ana... | 04/07/1998 |
| 5736516 | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein protein The present invention relates generally to methods for treating injury or degeneration of retinal neurons, and in particular photoreceptors, by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods... | 04/07/1998 |
| 5733874 | Stable dry powders The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.... | 03/31/1998 |
| 5733879 | Peptides and proteins, process for their preparation and their use as cholesterol acceptors The subject invention relates to amino acid sequences derived from peptide (Glu1,8, Leu11,17) 18A, comprising: Glu-Trp-Leu-A-Ala-B-Tyr-C-Lys-Val-D-Glu-Lys-Leu-Lys-Glu-Leu-Phe, wherein A is Lys, Glu or Asp; B is Phe, Glu or Asp; C is Glu, Lys o... | 03/31/1998 |
| 5733871 | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia... | 03/31/1998 |
| 5731284 | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product The present invention relates generally to methods for treating injury or degeneration of basal forebrain cholinergic neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating A... | 03/24/1998 |
| 5731287 | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates A process for the long term modification and regulation of lipid metaboli-generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human... | 03/24/1998 |
| 5728676 | Use of insulin-like growth factors I and II for inhibition of inflammatory response The present invention relates to methods for using IGF as inhibitors of inflammatory response, ischemic injury, and organ rejection.... | 03/17/1998 |
